The COVID-SED1 Study

Fernando Gómez-Peralta,Edelmiro Menéndez,Santiago Conde,Pablo Abellán-Galiana,Miguel Brito,Marina Beléndez,Antonio Pérez Pérez
DOI: https://doi.org/10.3390/jcm13071922
IF: 3.9
2024-03-27
Journal of Clinical Medicine
Abstract:Aims: To evaluate the metabolic and clinical outcomes in the Spanish type 1 diabetes mellitus (T1D) population before and after COVID-19 vaccination. Methods: A retrospective observational study was carried out in Spanish public hospitals previously enrolled in the SED1 study. Adults and children with T1D were included and their clinical electronic records were reviewed. Clinical, laboratory, and glucometric parameters from continuous glucose monitoring (CGM) data corresponding to the periods before and after administering the first COVID-19 vaccination were analyzed. Results: A total of 26 centers and 228 patients participated in this new phase of the SED1 study and 187 were finally evaluable (mean age 37.5 ± 15.6 years, 56.7% women). Overall, 94.6% of the sample was vaccinated, and this percentage increased with higher levels of education (p-value = 0.027). In the pre- and post-vaccination periods, respectively, the number of patients with acute hyperglycemic decompensation was 6/161 (3.7%) and 7/161 (4.3%) (p = 1) and with acute hypoglycemic decompensation was 6/161 (3.7%) and 6/161 (3.7%) (p = 1). The HbA1c level was lower in the post-vaccination period(mean ± SD, mg/dL): pre-vaccination 7.4 ± 0.9; post-vaccination 7.2 ± 1.0, (−0.19; p-value = 0.0006). A total of 31.9% of patients (95% CI: 24.7–39.7) in the pre-vaccination period and 45.0% (IC95%: 37.1–53.1) in the post-vaccine period had HbA1c < 7% (p-value < 0.001). Glucometrics from CGM data also showed numerical improvements post-vaccination. Conclusions: The COVID-19 vaccination was highly accepted in the Spanish T1D population, with hesitancy about the COVID-19 vaccine being higher in those with lower educational levels. A mildly better glycemic control was observed in the post-vaccination period.
medicine, general & internal
What problem does this paper attempt to address?
This paper aims to evaluate the metabolic and clinical outcomes of the Spanish type 1 diabetes (T1D) population before and after COVID - 19 vaccination. Specifically, the main objective of the study was to describe the changes in metabolic control (laboratory hemoglobin A1c - HbA1c - and the time of blood glucose in the range of 70 - 180 mg/dL - TIR) in T1D patients after COVID - 19 vaccination. In addition, the study also focused on overall blood - glucose control and variability (indicators derived from continuous glucose monitoring - CGM - data), complications related to T1D (such as hyperglycemic and hypoglycemic events), and the changes in COVID - 19 - related events before and after vaccination. ### Research Background Type 1 diabetes is an autoimmune disease targeting pancreatic β - cells, resulting in reduced insulin production. In recent years, the incidence and prevalence of T1D have increased globally. The COVID - 19 pandemic has had a significant impact on T1D patients, including fluctuations in blood - glucose control and changes in daily life. However, data on the impact of COVID - 19 vaccination on blood - glucose control and clinical endpoints in T1D patients are relatively limited. ### Research Methods - **Research Design**: This was a retrospective observational study that included a representative sample of T1D patients in 75 public hospitals in Spain. - **Primary Endpoint**: To evaluate the changes in metabolic control in T1D patients before and after COVID - 19 vaccination. - **Secondary Endpoint**: To evaluate overall blood - glucose control and variability, complications related to T1D (such as hyperglycemic and hypoglycemic events), and the changes in COVID - 19 - related events. - **Statistical Analysis**: Paired t - tests and McNemar tests were used for statistical analysis to compare the differences before and after vaccination. ### Main Findings - **Vaccination Acceptance**: 94.6% of T1D patients received COVID - 19 vaccination, and patients with a higher education level were more likely to be vaccinated (p - value = 0.027). - **Metabolic Control**: HbA1c levels decreased after vaccination (before vaccination: 7.4 ± 0.9%, after vaccination: 7.2 ± 1.0%, p - value = 0.0006). The proportion of patients with HbA1c < 7% increased from 31.9% to 45.0% (p - value < 0.001). - **Acute Hyperglycemic and Hypoglycemic Events**: There were no significant changes in the incidence of acute hyperglycemic and hypoglycemic events before and after vaccination (p - value = 1). - **CGM Data**: Although CGM data showed numerical improvements after vaccination, these changes did not reach statistical significance. ### Conclusions COVID - 19 vaccines are widely accepted among the Spanish T1D population, especially among patients with a higher education level. After vaccination, there was a slight improvement in the metabolic control of T1D patients, but the CGM data failed to show statistically significant changes. This may be due to the complex relationship between the immediate and long - term effects after vaccination, and other factors such as changes in diet and exercise patterns also affected the results. ### Significance This study provides important data on the impact of COVID - 19 vaccination on the metabolic control and clinical outcomes of T1D patients, which helps to better understand the role of vaccination in this special population.